SQI Diagnostics, Inc. engages in developing and selling testing kits, services, and automated testing systems to clinical laboratories, hospitals, clinicians, and diagnostic testing companies. It operates through the following segments: Development of Organ Health Diagnostic Tests; COVID-19-Related Diagnostics Tests; Direct-to-Consumer Tests for Celiac and Rheumatoid Arthritis Diseases; and Distribution of Existing COVID-19 Polymerase Chain Reaction and Antigen Tests. The company was founded by Peter Lea in 1999 and is headquartered in Toronto, Canada.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company